| Bid | 2.15 |
| Market Cap | 217.97M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.33 |
| PE Ratio (ttm) | -2.42 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 11.66 |
| Volume | 1,411,763 |
| Avg. Volume (20D) | 1,552,822 |
| Open | 3.40 |
| Previous Close | 3.40 |
| Day's Range | 3.15 - 3.40 |
| 52-Week Range | 2.70 - 19.10 |
| Beta | undefined |
About CATX
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facil...
Analyst Forecast
According to 9 analyst ratings, the average rating for CATX stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 520.16% from the latest price.
Next Earnings Release
Analysts project revenue of $232.76K, reflecting a -88.56% YoY shrinking and earnings per share of -0.26, making a -71.11% decrease YoY.
3 weeks ago · seekingalpha.com
Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAMPerspective Therapeutics' radiopharmaceuticals offer potential oncology applications by combining diagnostics with targeted therapeutics. I like the company's theranostics approach that delivers radia...
